AlphAIAlphAI — Financial news for AI agents
prnewswire.comSEP 152 min read$LLY

Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health

Eli Lilly (LLY) will present new data on its cardiometabolic drugs at EASD 2026. Retatrutide showed 20.8% weight loss and 1.6% A1C reduction in TRIUMPH-2. Foundayo (orforglipron) demonstrated cardiovascular benefits in ACHIEVE-4. Lilly will also share Phase 2 data for eloraTZP, a combination of eloralintide and tirzepatide.

Original reporting
prnewswire.com
Published Sep 15, 2026, 11:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 11:24 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health — source image
Source · prnewswire.com
Decision brief

The 30-second read

$LLYBullishMed
01

Why it matters

The disclosed data represent the first public disclosure of pivotal trial outcomes, likely to move the stock and sector.

02

Market read

First‑time release of pivotal trial data for multiple Lilly candidates; likely to affect Lilly's valuation and the cardiometabolic sector.

03

What to watch

Regulatory timelines and reimbursement landscape for oral GLP‑1 agents could limit upside despite strong data.

Relevance 8/10Novelty 9/10Timing: ahead of EASD 2026 conference (Sept 28‑Oct 2)

Background

Press release from Eli Lilly detailing upcoming presentations of late‑stage trial results for its cardiometabolic portfolio at EASD 2026.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Eli Lilly (LLY) announced new Phase 2 and Phase 3 trial data for retatrutide, eloraTZP and Foundayo at the upcoming EASD 2026 meeting.

Expected impact

Potential 3‑5% upside in the weeks following the conference as investors price in efficacy and safety signals.

Evidence & confidence

Phase 3 weight‑loss and A1C improvements are material; similar announcements have moved Lilly shares historically.

Market effects

Sector

Strengthens the broader cardiometabolic/obesity drug sector, pressuring peers such as Novo Nordisk and Pfizer.

Regional

Positive for US biotech and pharma indices; may lift European biotech exposure due to cross‑listing.

Global

Adds to global obesity‑treatment narrative, influencing investor sentiment worldwide.

Counterpoint

What could challenge this read

If efficacy data fall short of expectations or safety concerns emerge, the hype could reverse sharply.

Key entities

  • Company
    Eli Lilly and Company

    US‑listed pharmaceutical company (NYSE: LLY) developing obesity and diabetes therapies.

  • Drug
    retatrutide

    Investigational triple‑hormone receptor agonist in Phase 3.

  • Drug
    eloraTZP

    Combination of eloralintide and tirzepatide in Phase 2.

  • Drug
    Foundayo (orforglipron)

    Oral GLP‑1 agonist in Phase 3.

Read at source← All news

Related articles

SEP 15
$LLYHigh

Mounjaro's maker has more room to run amid GLP-1 boom, Berenberg says

Berenberg upgraded Eli Lilly to buy, raising its price target to $1,400, citing strong performance in the obesity market and potential upside in its GLP-1 drug pipeline. Shares have risen 52% over the past year, and the analyst expects further growth. Eli Lilly makes Mounjaro and Zepbound, with additional drugs in development. 27 of 34 analysts recommend buying the stock. Shares gained over 1% in premarket trading.

cnbc.com2 min
SEP 15
$LLYMedAI 8/10

Eli Lilly Vs. Merck: One is a No

Eli Lilly (LLY) reported Q2 revenue of $23B, up 48% YoY, driven by Mounjaro and Zepbound. Merck (MRK) saw 5% growth to $16.6B, with KEYTRUDA nearing peak penetration. Lilly raised FY2026 guidance to $85-87B and boasts an 86% gross margin. Merck's strategy focuses on new drugs like Lipvendra and WINREVAIR.

aol.com3 min
SEP 15
$LLYHighAI 8/10

Berenberg bullish on Eli Lilly, sees nearly 25% upside

Berenberg upgraded Eli Lilly (LLY) to 'buy' with a $1,400 price target, citing 25% upside potential. Analyst Kerry Holford praised Lilly's leadership in obesity and diabetes markets, strong R&D returns, and diverse pipeline investments, including recent acquisitions. The stock trades at a premium valuation, justified by superior growth and research productivity, according to the analyst.

investing.com2 min
SEP 15
$LLYMed

Why is Eli Lilly stock climbing today?

Eli Lilly (LLY) stock rose 1.6% in pre-market trading to $1,155.96. Analyst Berenberg upgraded it to Buy with a $1,400 price target, citing strong performance in obesity drugs and upcoming diabetes approvals. The company's Foundayo drug captured 30% of the U.S. oral obesity market since its April launch. Analysts' average price target is near $1,300. Broader markets are down ahead of the Fed meeting.

investing.com2 min